Table 4.
Factors associated with achieving disease control with subsequent chemotherapy
| Variable | Disease control with subsequent chemotherapy (all patients) | Disease control with sPBC | Disease control with sNPBC | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Yes (N = 135), a n (%) | No (N = 132),a n (%) | p value | Yes (N = 70), a n (%) | No (N = 52), a n (%) | p value | Yes (N = 65),a n (%) | No (N = 80),a n (%) | p value | |
| ECOG PS | .065 | .384 | .334 | ||||||
| 0 | 32 (29.4) | 20 (19.2) | 19 (32.8) | 10 (24.4) | 13 (25.5) | 10 (15.9) | |||
| 1 | 63 (57.8) | 57 (54.8) | 33 (56.9) | 22 (53.7) | 30 (58.8) | 35 (55.6) | |||
| ≥2 | 14 (12.8) | 27 (26.0) | 6 (10.3) | 9 (22.0) | 8 (15.7) | 18 (28.6) | |||
| CCI | .345 | .403 | .910 | ||||||
| 0 | 60 (44.4) | 61 (46.2) | 32 (45.7) | 25 (48.1) | 28 (43.1) | 36 (45.0) | |||
| 1 | 14 (10.4) | 6 (4.5) | 10 (14.3) | 3 (5.8) | 4 (6.2) | 3 (3.8) | |||
| 2 | 26 (19.3) | 27 (20.5) | 11 (15.7) | 7 (13.5) | 15 (23.1) | 20 (25.0) | |||
| ≥3 | 35 (25.9) | 38 (28.8) | 17 (24.3) | 17 (32.7) | 18 (27.7) | 21 (26.3) | |||
| Liver metastases | .016 | .038 | .147 | ||||||
| Yes | 31 (23.0) | 48 (36.9) | 14 (20.0) | 18 (36.0) | 17 (26.2) | 30 (37.5) | |||
| No | 104 (77.0) | 82 (63.1) | 56 (80.0) | 32 (64.0) | 48 (73.9) | 50 (62.5) | |||
| Number of fPBC cycles | .340 | .193 | .703 | ||||||
| 2 | 14 (10.4) | 11 (8.3) | 7 (10.0) | 5 (9.6) | 7 (10.8) | 6 (7.5) | |||
| 3–4 | 43 (31.9) | 31 (23.5) | 24 (34.3) | 11 (21.1) | 19 (29.2) | 20 (25.0) | |||
| 5–6 | 63 (46.7) | 70 (53.0) | 35 (50.0) | 28 (53.8) | 28 (43.1) | 42 (52.5) | |||
| ≥7 | 15 (11.1) | 20 (15.2) | 4 (5.7) | 8 (15.4) | 11 (16.9) | 12 (15.0) | |||
| Best response with fPBC | .002 | .002 | .185 | ||||||
| Disease control | 99 (78.6) | 75 (60.5) | 55 (87.3) | 32 (62.7) | 44 (69.8) | 43 (58.9) | |||
| Progressive disease | 27 (21.4) | 49 (39.5) | 8 (12.7) | 19 (37.3) | 19 (30.2) | 30 (41.1) | |||
| Months elapsed since fPBC, median (IQR) | 3.9 (1.0–8.9) | 2.8 (1.1–5.5) | .051 b | 6.0 (1.5–10.1) | 2.9 (1.1–5.4) | .008 b | 2.2 (0.9–6.6) | 2.6 (1.0–5.6) | .769 b |
a
Total number of patients for some variables may be less than “N” because of missing values. Due to rounding, some columns may not add up to 100.0%.
b
Mann‐Whitney U test used to compare nonparametric data.
Abbreviations: CCI, Charlson Comorbidity Index; ECOG PS, Eastern Cooperative Oncology Group performance status; fPBC, first‐line platinum‐based chemotherapy; IQR, interquartile range; sNPBC, subsequent non–platinum‐based chemotherapy; sPBC, subsequent platinum‐based chemotherapy.